The benefit of immunotherapy, such as anti-PD1 or anti-PD-L1 antibodies, in NSCLC will be assessed in ongoing or in future studies (NCT02768558, NCT0257843) [34,35]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.